Skip to main content

Takhzyro 300 mg injectable solution

Prescription request online

Prescription request online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

Doctor
5.0(6)

Jorge Correa Bellido

General medicine7 years of experience
Licence no. 464626297

Dr. Jorge Correa Bellido is a Spanish physician who offers online consultations in Spanish and English. He graduated from the University of La Laguna and has a solid background in clinical practice and international research.

Throughout his career, he has participated in various medical and academic projects, including a research fellowship in Spain, where he contributed to evidence-based studies in the field of family medicine. This experience allowed him to broaden his global perspective on healthcare and comprehensive patient care.

Dr. Correa Bellido has worked with several healthcare providers in Spain, focusing particularly on patient-centered care and public health initiatives aimed at communities with limited access to healthcare services.

In addition, he actively participates in international medical conferences and workshops, which allows him to stay up to date with the latest medical advances and collaborate with healthcare professionals from different countries.

Dr. Correa Bellido provides comprehensive care for a wide variety of medical conditions, including:

  • respiratory infections
  • gastrointestinal disorders
  • cardiovascular problems
  • endocrine and metabolic diseases
  • musculoskeletal and dermatological conditions
  • as well as mental health conditions such as anxiety and depression.

He also treats infectious and allergic diseases, general health concerns, and provides guidance on prevention and healthy lifestyle habits.

His services include virtual consultations, diagnosis and management of acute and chronic diseases, prescription renewals, and personalized medical advice.

With a patient-centered approach and a strong commitment to continuous learning, Dr. Correa Bellido provides accessible and high-quality healthcare to patients both in Spain and around the world.

Book a video appointment
€86
This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use TAKHZYRO 300 mg INJECTABLE SOLUTION

Contents of the leaflet

  1. Introduction
  2. What is TAKHZYRO and what is it used for
  3. What you need to know before you use TAKHZYRO
  4. How to use TAKHZYRO
  5. Possible side effects
  6. Storage of TAKHZYRO
  7. Container Contents and Additional Information

Introduction

Package Leaflet: Information for the User

TAKHZYRO300mg solution for injection in vial

lanadelumab

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is TAKHZYRO and what is it used for
  2. What you need to know before you use TAKHZYRO
  3. How to use TAKHZYRO
  4. Possible side effects
  5. Storage of TAKHZYRO
  6. Contents of the pack and other information
  7. Instructions for use

1. What is TAKHZYRO and what is it used for

TAKHZYRO contains the active substance lanadelumab.

What is TAKHZYRO used for

TAKHZYRO is a medicine used in patients from 2 years of age with hereditary angioedema (HAE) to prevent angioedema attacks.

What is hereditary angioedema (HAE)

HAE is a hereditary disease within the same family. When you have this disease, there is not enough of a protein called "C1 inhibitor" in the blood, or the C1 inhibitor does not work properly. This leads to an excess of "plasma kallikrein", which in turn produces higher levels of "bradykinin" in the bloodstream. Too much bradykinin causes HAE symptoms, such as swelling and pain in:

  • the hands and feet
  • the face, eyelids, lips, or tongue
  • the vocal cords (larynx), which can make it difficult to breathe
  • the genitals

How TAKHZYRO works

TAKHZYRO is a type of protein that blocks the activity of plasma kallikrein, which helps to reduce the amount of bradykinin present in the bloodstream and prevents HAE symptoms.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use TAKHZYRO

Do not use TAKHZYRO

If you are allergic to lanadelumab or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

  • Talk to your doctor, pharmacist, or nurse before starting to use TAKHZYRO.
  • If you have a severe allergic reaction to TAKHZYRO with symptoms such as rash, chest tightness, wheezing, or rapid heartbeat, tell your doctor, pharmacist, or nurse immediately.

Keep a record

It is strongly recommended that each time you are given a dose of TAKHZYRO, you note the name and batch number of the medicine, so that you have a record of the batches used.

Lab tests

Tell your doctor if you are using TAKHZYRO before undergoing lab tests to evaluate your blood clotting, as the presence of TAKHZYRO in the blood may interfere with certain lab tests and lead to inaccurate results.

Children and adolescents

TAKHZYRO is not recommended for use in children under 2 years of age, as it has not been studied in this age group.

Other medicines and TAKHZYRO

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

It is not known whether TAKHZYRO affects other medicines or is affected by other medicines.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using TAKHZYRO. Information on the safety of using TAKHZYRO during pregnancy and breastfeeding is limited. As a precaution, it is recommended to avoid using lanadelumab during pregnancy and breastfeeding. Your doctor will discuss with you the risks and benefits of receiving this medicine.

Driving and using machines

This medicine has no or negligible influence on the ability to drive and use machines.

TAKHZYRO contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per vial, which is essentially "sodium-free".

3. How to use TAKHZYRO

TAKHZYRO comes in single-use vials as a ready-to-use solution. A doctor with experience in treating patients with HAE will start and supervise your treatment.

Follow the instructions for administration of the medicine contained in this leaflet or as directed by your doctor, pharmacist, or nurse. If you have any doubts or other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.

How much TAKHZYRO to use

For adults and adolescents from 12 years to less than 18 years of age:

  • The recommended starting dose is 300 mg of lanadelumab every 2 weeks. If you have not had any attacks for a long period, your doctor may change your dose to 300 mg of lanadelumab every 4 weeks, especially if your body weight is low.
  • In patients with a body weight below 40 kg, a starting dose of 150 mg of lanadelumab every 2 weeks may also be considered. If you have not had any attacks for a long period, your doctor may change your dose to 150 mg of lanadelumab every 4 weeks.

For children from 2 years to less than 12 years of age, the recommended starting dose is based on body weight:

Body weight (kg)

Recommended starting dose

Dose adjustment

10 to less than 20 kg

150 mg of lanadelumab every 4 weeks

A dose increase to 150 mg of lanadelumab every 3 weeks may be considered in patients with insufficient control of attacks

20 to less than 40 kg

150 mg of lanadelumab every 2 weeks

A dose reduction to 150 mg of lanadelumab every 4 weeks may be considered in stable patients without attacks under treatment

40 kg or more

300 mg of lanadelumab every 2 weeks

A dose reduction to 300 mg of lanadelumab every 4 weeks may be considered in stable patients without attacks under treatment

  • In patients with a body weight of 20 to less than 40 kg who have not had any attacks for a long period, the doctor may allow your child to continue receiving the same dose when they reach 12 years of age.

How to inject TAKHZYRO

If you self-inject TAKHZYRO or if it is injected by your caregiver, you or your caregiver must read and follow the instructions in section 7, "Instructions for use" carefully.

  • TAKHZYRO is injected under the skin ("subcutaneous injection").
  • The injection can be given by you or a caregiver in patients from 12 years of age.
  • The injection can be given by a healthcare professional or by a caregiver in patients from 2 years to less than 12 years of age.
  • A doctor, pharmacist, or nurse should teach you how to prepare and inject TAKHZYRO correctly before you use it for the first time. Do not inject yourself or inject someone else until you have been taught how to inject the medicine.
  • Insert the needle into the fatty tissue of the stomach (abdomen), thigh, or upper arm.
  • Inject the medicine into a different place each time.
  • Use each vial of TAKHZYRO only once.

If you use more TAKHZYRO than you should

Tell your doctor, pharmacist, or nurse if you have been given a dose of TAKHZYRO that is higher than recommended.

If you forget to use TAKHZYRO

If you miss a dose of TAKHZYRO, inject the dose as soon as possible. The administration of subsequent doses may require an adjustment according to the desired dosing frequency, making sure to:

  • wait at least 10 days between doses in patients with a dosing regimen every 2 weeks,
  • wait at least 17 days between doses in patients with a dosing regimen every 3 weeks,
  • wait at least 24 days between doses in patients with a dosing regimen every 4 weeks.

If you are not sure when to inject TAKHZYRO after missing a dose, ask your doctor, pharmacist, or nurse.

If you stop treatment with TAKHZYRO

It is important that you keep injecting TAKHZYRO as your doctor has told you, even if you feel better.

If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you have a severe allergic reaction to TAKHZYRO with symptoms such as rash, chest tightness, wheezing, or rapid heartbeat, tell your doctor, pharmacist, or nurse immediately.

Tell your doctor, pharmacist, or nurse if you notice any of the following side effects.

Very common (may affect more than 1 in 10 people):

  • Reactions at the injection site: symptoms are pain, redness of the skin, bruising, discomfort, swelling, bleeding, itching, hardening of the skin, tingling, warmth, and rash.

Common (may affect up to 1 in 10 people):

  • Allergic reactions, such as itching, discomfort, and tingling in the tongue
  • Dizziness, feeling of fainting
  • Raised rash
  • Muscle pain
  • Lab test results showing changes in the liver

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of TAKHZYRO

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date is the last day of the month stated.

Store in a refrigerator (between 2°C and 8°C). Do not freeze. Keep the vial in the outer packaging to protect it from light.

The vials can be stored below 25°C for a single period of 14 days but without exceeding the expiry date.

After storage at room temperature, do not refrigerate TAKHZYRO again for storage.

Do not use this medicine if you notice signs of deterioration, such as particles in the vial or a change in the color of the injection solution.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Contents and Additional Information

TAKHZYRO Composition

  • The active ingredient is lanadelumab. Each vial contains 300 mg of lanadelumab in 2 ml solution.
  • The other components are disodium phosphate dihydrate, citric acid monohydrate, histidine, sodium chloride, polysorbate 80, and water for injectable preparations; see section 2 "TAKHZYRO contains sodium".

Product Appearance and Container Contents

TAKHZYRO is presented as a clear, colorless to pale yellow injectable solution in a glass vial.

TAKHZYRO is available as a single-unit package that contains a 2 ml vial and as multiple packages that contain 2 or 6 intermediate boxes, each with 1 vial.

Not all pack sizes may be marketed.

Each package also contains the following components:

  • A 3 ml empty syringe
  • A 18-gauge vial access needle with a blunt tip
  • A 27 G x 13 mm injection needle with a sharp tip

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Takeda Pharmaceuticals International AG Ireland Branch

Block 2 Miesian Plaza

50-58 Baggot Street Lower

Dublin 2

D02 HW68

Ireland

Manufacturer

Takeda Pharmaceuticals International AG Ireland Branch

Block 2 Miesian Plaza

50-58 Baggot Street Lower

Dublin 2

D02 HW68

Ireland

Shire Pharmaceuticals Ireland Limited

Blocks 2 & 3 Miesian Plaza

50-58 Baggot Street Lower

Dublin 2

Ireland

You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:

Belgium/Belgique/Belgien

Takeda Belgium NV

Tel: +32 2 464 06 11

[email protected]

Lithuania

Takeda, UAB

Tel: +370 521 09 070

[email protected]

Text in Bulgarian language with contact information of Takeda Bulgaria EOOD including phone and email

Luxembourg/Luxemburg

Takeda Belgium NV

Tel: +32 2 464 06 11

[email protected]

Czech Republic

Takeda Pharmaceuticals Czech Republic s.r.o.

Tel: +420 234 722 722

[email protected]

Hungary

Takeda Pharma Kft.

Tel: +36 1 270 7030

[email protected]

Denmark

Takeda Pharma A/S

Tel: +45 46 77 10 10

[email protected]

Malta

Drugsales Ltd

Tel: +356 21419070

[email protected]

Germany

Takeda GmbH

Tel: +49 (0)800 825 3325

[email protected]

Netherlands

Takeda Nederland B.V.

Tel: +31 20 203 5492

[email protected]

Estonia

Takeda Pharma OÜ

Tel: +372 6177 669

[email protected]

Norway

Takeda AS

Tel: +47 800 800 30

[email protected]

Greece

Τakeda ΕΛΛΑΣ Α.Ε.

Tel: +30 210 6387800

[email protected]

Austria

Takeda Pharma Ges.m.b.H.

Tel: +43 (0) 800-20 80 50

[email protected]

Spain

Takeda Farmacéutica España, S.A.

Tel: +34 917 90 42 22

[email protected]

Poland

Takeda Pharma Sp. z o.o.

Tel: +48223062447

[email protected]

France

Takeda France SAS

Tel: + 33 1 40 67 33 00

[email protected]

Portugal

Takeda Farmacêuticos Portugal, Lda.

Tel: + 351 21 120 1457

[email protected]

Croatia

Takeda Pharmaceuticals Croatia d.o.o.

Tel: +385 1 377 88 96

[email protected]

Romania

Takeda Pharmaceuticals SRL

Tel: +40 21 335 03 91

[email protected]

Ireland

Takeda Products Ireland Ltd

Tel: 1800 937 970

[email protected]

Slovenia

Takeda Pharmaceuticals farmacevtska družba d.o.o.

Tel: + 386 (0) 59 082 480

[email protected]

Iceland

Vistor ehf.

Tel: +354 535 7000

[email protected]

Slovakia

Takeda Pharmaceuticals Slovakia s.r.o.

Tel: +421 (2) 20 602 600

[email protected]

Italy

Takeda Italia S.p.A.

Tel: +39 06 502601

[email protected]

Finland

Takeda Oy

Tel: 0800 774 051

[email protected]

Cyprus

Proton Medical (Cyprus) Ltd

Tel: +357 22866000

[email protected]

Sweden

Takeda Pharma AB

Tel: 020 795 079

[email protected]

Latvia

Takeda Latvia SIA

Tel: +371 67840082

[email protected]

United Kingdom (Northern Ireland)

Takeda UK Ltd

Tel: +44 (0) 3333 000 181

[email protected]

Date of the Last Revision of this Leaflet:

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.

  1. Instructions for Use

Make sure to read, understand, and follow the step-by-step instructions for injecting TAKHZYRO. Contact your doctor, pharmacist, or nurse if you have questions.

In addition to the vial, each TAKHZYRO package also contains:

  • A 3 ml empty syringe.

Transparent syringe with black plunger showing measurement marks in milliliters and a graduated cylinder

  • A 18-gauge vial access needle with a blunt tip.

This is used to withdraw the solution from the vial to the syringe.

Hypodermic needle with beveled tip and light gray metal body on a white background

  • A 27 G x 13 mm injection needle with a sharp tip.

This is used for subcutaneous injection.

Gray-colored hypodermic needle with sharp bevel and elongated metal cylinder for connection to syringe

Use only the syringes, vial access needles with blunt tips, and injection needles with sharp tips that come in this package or that your doctor has prescribed.

Use the syringes, vial access needles with blunt tips, and injection needles with sharp tips only once. Place all used syringes and needles in a puncture-proof container.

Do not use a syringe, vial access needle with a blunt tip, or injection needle with a sharp tip that appears to be damaged.

You will also need:

  • Alcohol swabs
  • A puncture-proof container for used vials, needles, and syringes

You can obtain these items from your doctor, pharmacist, or nurse.

The injection of TAKHZYRO can be summarized in 5 steps:

  1. Preparation of the TAKHZYRO vial
  2. Attaching the vial access needle with a blunt tip to the syringe
  3. Transferring TAKHZYRO to the syringe and changing to the injection needle with a sharp tip
  4. Selection and preparation of the injection site
  5. Injection of TAKHZYRO

Step 1: Preparation of the TAKHZYRO vial

Hand holding a vial of medication with grayish liquid and a silver cap turning clockwise

  1. Remove the vial from the refrigerator 15 minutes before use to allow it to reach room temperature (between 15°C and 25°C) before preparing an injection.
  2. Clean the work area and wash your hands before preparing the dose. Do not touch any surface or touch your body, especially your face, after washing your hands before injection.
  3. Gather TAKHZYRO and the other components and place them on the well-lit work surface you are using.
  4. Remove the vial from the package. Do not use the vial if the cap that covers the stopper is missing.
  5. Gently invert the vial 3 to 5 times to ensure the solution is mixed. Do not shake the vial, as this may cause foam to form.
  6. Check that the solution in the vial does not contain particles or has changed color (it is usually colorless to pale yellow). Do not use if you see particles or a color change.

Important warning in red that says “Do not shake” on a black rectangular background

Hand holding a vial of medication with the cap partially removed and a black arrow pointing upwards

  1. Remove the plastic cap from the vial. Do not remove the rubber stopper.

Glass vial with liquid and hand applying a swab or gauze to its upper opening

  1. Place the vial on a flat surface. Use an alcohol swab to clean the rubber stopper of the vial and let it dry.

Step 2: Attaching the vial access needle with a blunt tip to the syringe

Hand holding a syringe with needle inserted into the skin, black safety device activated over the needle

  1. Screw the 18-gauge vial access needle with a blunt tip onto the 3 ml syringe.

Important warning about not removing the needle protection when attaching to the syringe, text framed in a black box

Hand holding a black pen with the tip pointing forward and slightly upwards

  1. Pull the plunger to fill the syringe with an amount of air equal to the amount of solution in the vial.

Hands holding a pre-filled syringe and an injection device with exposed needle preparing for administration

  1. Separate the needle cap in a straight line without touching the needle. Do not pull the plunger.

Step 3: Transferring TAKHZYRO to the syringe and changing to the injection needle with a sharp tip

Hand holding a syringe withdrawing medication from a transparent vial with a black arrow indicating the direction

  1. Insert the needle into the center of the rubber stopper.
  1. Press the plunger to inject air into the vial and hold it pressed.

Hand filling a syringe with liquid from a transparent vial, close-up detail shows liquid level and plunger descending

  1. Slowly invert the vial with the needle and syringe attached. Pull the plunger to withdraw the complete dosethat comes in the vial.

Text in a black box indicating to keep the needle tip in the liquid to avoid drawing air when pulling the plunger

Hand filling a syringe with liquid from a vial, close-up detail of the needle inserted and plunger being pulled upwards

Two pre-filled syringes shown vertically, one with a checkmark and the other with a red cross indicating correct and incorrect

  1. Eliminate large air bubbles by gently tapping the syringe with your fingers until the bubbles rise to the top of the syringe.

Slowly press the plunger, allowing the air to return to the vial until the solution reaches the top of the syringe.

Repeat these steps until the large air bubbles have been eliminated.

Hand holding an auto-injector with the protective cap removed preparing to inject into the abdomen

  1. Without removing the needle from the vial, unscrew the syringe by holding the top part of the needle and turning the syringe counterclockwise.

Put the syringe back in a vertical position.

Gray medical waste container with black lid and biological hazard symbol triangular in relief on the front

  1. Place the 18-gauge vial access needle with a blunt tip and the vial in a puncture-proof container.

Hand holding an auto-injector with a black arrow indicating the direction of injection into the skin

  1. Screw the 27 G x 13 mm injection needle with a sharp tip onto the syringe

Text in a white box with a warning not to remove the needle cap when attaching to the syringe and not to use vial access needles

Step 4: Selection and Preparation of the Injection Site

Human silhouette with shaded areas on thighs, abdomen, shoulders, and hips indicating possible injection sites

Human body diagram showing shaded areas on the upper outer part of both arms

  1. Choose an injection site on the stomach (abdomen), thigh, or upper arm. The injection should be administered subcutaneously.
  1. Clean the injection site with an alcohol swab and let the skin dry completely.

Important text about injections: using different sites, avoiding scars and purple or swollen areas, not injecting into the outer arm

Step 5: Injection of TAKHZYRO

Hands holding an auto-injector with the needle exposed pointing forward

  1. Remove the needle cap in a straight line without touching the needle. Do not pull the plunger. Do not touch the needle tip or allow it to touch any other surface.

Important text about injecting TAKHZYRO within 2 hours of preparation and refrigeration options

Hand holding a syringe with needle inserted into the skin of the arm, arrow indicates direction of injection

  1. Gently pinch about 3 cm of skin at the cleaned injection site and insert the needle.

Schematic representation of the skin showing the subcutaneous layer and muscle with explanatory text about the injection

Hand holding a pre-filled syringe with needle inserted into the skin with an arrow indicating the direction of injection

  1. Slowly press the plunger until all the medicine has been injected. Release the skin fold and carefully remove the needle. Do not replace the needle cap.

Gray medical waste container with black lid and biological hazard symbol triangular visible on the front

  1. Place the 27 G x 13 mm injection needle with a sharp tip and the syringe in a puncture-proof container.

Online doctors for TAKHZYRO 300 mg INJECTABLE SOLUTION

Discuss questions about TAKHZYRO 300 mg INJECTABLE SOLUTION, including use, safety considerations and whether a prescription is appropriate, subject to medical assessment and local regulations.

Doctor
5.0(6)

Jorge Correa Bellido

General medicine7 years of experience
Licence no. 464626297

Dr. Jorge Correa Bellido is a Spanish physician who offers online consultations in Spanish and English. He graduated from the University of La Laguna and has a solid background in clinical practice and international research.

Throughout his career, he has participated in various medical and academic projects, including a research fellowship in Spain, where he contributed to evidence-based studies in the field of family medicine. This experience allowed him to broaden his global perspective on healthcare and comprehensive patient care.

Dr. Correa Bellido has worked with several healthcare providers in Spain, focusing particularly on patient-centered care and public health initiatives aimed at communities with limited access to healthcare services.

In addition, he actively participates in international medical conferences and workshops, which allows him to stay up to date with the latest medical advances and collaborate with healthcare professionals from different countries.

Dr. Correa Bellido provides comprehensive care for a wide variety of medical conditions, including:

  • respiratory infections
  • gastrointestinal disorders
  • cardiovascular problems
  • endocrine and metabolic diseases
  • musculoskeletal and dermatological conditions
  • as well as mental health conditions such as anxiety and depression.

He also treats infectious and allergic diseases, general health concerns, and provides guidance on prevention and healthy lifestyle habits.

His services include virtual consultations, diagnosis and management of acute and chronic diseases, prescription renewals, and personalized medical advice.

With a patient-centered approach and a strong commitment to continuous learning, Dr. Correa Bellido provides accessible and high-quality healthcare to patients both in Spain and around the world.

Book a video appointment
€86
Doctor
5.0(21)

Nuno Tavares Lopes

General medicine18 years of experience

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies

  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management

  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses

  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment

  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance

  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis

  • Pain management: acute and chronic pain, post-surgical care

  • Public health: prevention, health screenings, long-term monitoring

  • Sick leave (Baixa médica) connected to Segurança Social in Portugal

  • IMT medical certificates for driving licence exchange

Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Book a video appointment
€70
Doctor

Hocine Lokchiri

General medicine21 years of experience

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Book a video appointment
€64
Doctor
4.7(11)

Anastasiia Shalko

General medicine13 years of experience
Licence no. 52891

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate

Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Book a video appointment
€56
Doctor
5.0(1)

Cristina Andrada Brazo

General medicineSleep medicine16 years of experience
Licence no. 264505958

Dr. Cristina Andrada Brazo is a highly experienced Spanish physician with more than 15 years of clinical practice in emergency medicine, urgent care, and clinical neurophysiology. She provides professional online medical consultations for patients across Spain, helping both residents and international visitors receive timely medical advice, diagnosis, treatment recommendations, and electronic prescriptions when clinically appropriate.

As a licensed physician fully integrated with the Spanish electronic prescription system, Dr. Andrada can issue legally valid e-prescriptions following a medical assessment during an online consultation. Whether you need help with an acute illness, prescription renewal, neurological symptoms, or travel-related healthcare, she offers convenient, patient-centered medical care without the need to visit a clinic.

Dr. Andrada combines extensive emergency medicine experience with advanced expertise in neurology, epilepsy, sleep medicine, and headache disorders. Her international clinical background includes several years working in Switzerland, where she collaborated with multidisciplinary teams in emergency departments and neurology services. This experience strengthened her commitment to evidence-based medicine, compassionate communication, and high-quality patient care.

She graduated in Medicine from the University of Seville and completed her residency in Clinical Neurophysiology at Hospital Virgen de la Salud and the National Hospital for Paraplegics in Toledo. She currently works as a Clinical Neurophysiology Specialist at Hospital San Pedro in Logroño.

To further expand her expertise, Dr. Andrada completed several postgraduate qualifications, including Master's degrees in Sleep Physiology and Medicine, Medical Professionalism and Clinical Practice, Epilepsy, and Clinical Management.

Patients appreciate her thorough consultations, practical treatment recommendations, and empathetic approach. She speaks Spanish, French, and Portuguese, allowing her to communicate comfortably with patients from different backgrounds.

Conditions Dr. Cristina Andrada Treats Online

Dr. Andrada provides online consultations for a wide range of common medical conditions, including:

  • Fever, flu, COVID-19 symptoms, sore throat and respiratory infections
  • Sinusitis, bronchitis, cough and seasonal allergies
  • Urinary tract infections (UTIs)
  • Migraine and tension headaches
  • Dizziness and vertigo
  • Epilepsy and seizure follow-up
  • Sleep disorders, including insomnia and circadian rhythm disturbances
  • Heartburn, gastritis, diarrhea and constipation
  • Back pain, muscle injuries and joint pain
  • Minor skin infections and allergic reactions
  • Fatigue and general medical assessment
  • Prescription renewals for appropriate chronic treatments
  • Follow-up consultations after surgery or previous medical treatment
  • Travel medicine advice and preventive healthcare
  • Interpretation of laboratory results and medical reports

If your condition requires urgent in-person assessment or emergency care, Dr. Andrada will advise you on the most appropriate next steps.

Book an Online Consultation

Book a secure online consultation with Dr. Cristina Andrada Brazo through Oladoctor and receive professional medical advice from an experienced Spanish physician without leaving home. Online appointments are available for adults throughout Spain, with fast access to medical care and electronic prescriptions whenever clinically indicated.

Book a video appointment
€56
Doctor
5.0(8)

Lizaveta Trafimchuk Takhvaniuk

DermatologyGeneral medicine10 years of experience
Licence no. 58788

Dr. Lizaveta Trafimchuk Takhvaniuk graduated in Medicine and subsequently specialized in Dermatology and Venereology. She has more than 10 years of clinical experience and is licensed to practice in Spain, where she focuses on the comprehensive diagnosis and treatment of dermatological conditions.

Throughout her education and professional career, Dr. Trafimchuk has gained extensive experience in managing diseases of the skin, hair, and nails, as well as in the diagnosis, treatment, and prevention of sexually transmitted infections (STIs). Her clinical approach is based on evidence-based medicine, combined with personalized care tailored to each patient’s needs.

In her daily practice, she treats a wide range of dermatological conditions, including chronic inflammatory dermatoses such as acne, rosacea, atopic dermatitis, psoriasis, and eczema. She also has experience in treating pigmentation disorders, including melasma, post-inflammatory hyperpigmentation, and dyschromia.

She has developed a particular interest in trichology, treating various types of alopecia, chronic hair loss, and scalp disorders. In addition, she has experience in managing infectious dermatoses of fungal, viral, and bacterial origin, as well as in evaluating benign and suspicious skin lesions, with referral to specialized care when necessary.

With a strong interest in a comprehensive approach to skin health, she also treats scars, post-procedural skin changes, and conditions related to hormonal factors and aging, including those associated with pregnancy, menopause, and age-related skin changes.

Thanks to her experience and continuous professional development, Dr. Trafimchuk provides high-quality medical care that is professional, confidential, and aligned with modern dermatology standards.

Book a video appointment
€72

Frequently Asked Questions

TAKHZYRO 300 mg INJECTABLE SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.

The active ingredient in TAKHZYRO 300 mg INJECTABLE SOLUTION is lanadelumab. This information helps identify medicines with the same composition but different brand names.

TAKHZYRO 300 mg INJECTABLE SOLUTION is manufactured by Takeda Pharmaceuticals International Ag Ireland Branch. Pharmacy brands and packaging may differ depending on the distributor.

Doctors such as Family doctors, Cardiologists, Nephrologists, Hematologists, General surgeons, General medicine doctors, Phlebologists may assess whether TAKHZYRO 300 mg INJECTABLE SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.

The prescription is issued by a doctor after assessing your health. In Spain, TAKHZYRO 300 mg INJECTABLE SOLUTION is then dispensed in pharmacies with that prescription. An online consultation does not guarantee that a prescription will be issued: the decision always rests with the doctor.

To request an assessment, you can use Oladoctor:

Other medicines with the same active substance (lanadelumab) include TAKHZYRO 150 mg Injectable Solution in Pre-filled Syringe, TAKHZYRO 300 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, ANDEMBRY 200 mg INJECTABLE SOLUTION IN PRE-FILLED PEN. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media